Atlas Trials

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Clinical trial NCT05833126 · UNKNOWN

Trial details

NCT number
NCT05833126
Sponsor
Shuhong Yi
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Liver Cancer After Liver Transplantation
Start date
2023-12-03
Primary completion
2024-12-31
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.